Health Economics›Hepatocellular carcinoma›Advanced or metastatic disease second-line

Advanced or metastatic disease second-line

Hepatocellular carcinoma · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	14.3 mo	52	R 14 921 674 PFS proxy	2
Regorafenib monotherapy Variant #01	—	R 132 655	28d	—	10.6 mo	2	R 265 310 PFS proxy	1
Ramucirumab monotherapy Variant #01	—	R 48 173	14d	—	8.9 mo	2	R 96 346 PFS proxy	2
Placebo Partial	—	—	—	2.3 mo	7.7 mo	—	—	13

4 of 4 regimens shown